8C5 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
LOQTORZI Commercial GrowthLOQTORZI is establishing a growing oncology revenue base, supported by increased patient starts and improving treatment duration. Sustained quarterly growth could diversify revenue toward immuno-oncology and provide a platform for future pipeline commercialization.
Lower Operating Cost StructureRepeated reductions in R&D and SG&A indicate a leaner operating model following the biosimilar divestiture. Continued cost discipline can extend the company’s funding runway and improve operating leverage if LOQTORZI and pipeline revenues scale.
Reduced Debt And Extended MaturitiesThe refinancing lengthens maturities, lowers the burden of the previous facility and provides working-capital flexibility through optional tranches. This supports execution across upcoming oncology launches, although covenants and secured borrowing remain constraints.
Bears Say
Severe Cash Burn And Funding DependenceThe company is not currently self-funding operations, leaving it dependent on cost reductions, product growth, asset monetization or additional capital. Persistent burn could restrict investment in clinical programs and increase financing risk before profitability is reached.
Unstable Revenue Base And Deep LossesLarge revenue swings and deeply negative margins show that the business has not yet achieved a stable commercial earnings base. The transition from biosimilars to oncology increases reliance on successful adoption and execution of a narrower product portfolio.
Clinical Data And Execution UncertaintyThe main pipeline value drivers still depend on data maturation and formal analysis. Early efficacy and biomarker signals may change as datasets are cleaned and expanded, creating meaningful development, regulatory and commercialization risk over the next several quarters.
Coherus Biosciences News
8C5 FAQ
What was Coherus Biosciences’s price range in the past 12 months?
Currently, no data Available
What is Coherus Biosciences’s market cap?
Coherus Biosciences’s market cap is CHF170.44M.
When is Coherus Biosciences’s upcoming earnings report date?
Coherus Biosciences’s upcoming earnings report date is Nov 09, 2026 which is in 73 days.
How were Coherus Biosciences’s earnings last quarter?
Coherus Biosciences released its earnings results on Aug 05, 2026. The company reported -CHF0.179 earnings per share for the quarter, beating the consensus estimate of -CHF0.203 by CHF0.024.
Is Coherus Biosciences overvalued?
According to Wall Street analysts Coherus Biosciences’s price is currently Undervalued.
Does Coherus Biosciences pay dividends?
Coherus Biosciences does not currently pay dividends.
What is Coherus Biosciences’s EPS estimate?
Coherus Biosciences’s EPS estimate is -0.18.
How many shares outstanding does Coherus Biosciences have?
Coherus Biosciences has 154,500,960 shares outstanding.
What happened to Coherus Biosciences’s price movement after its last earnings report?
Coherus Biosciences reported an EPS of -CHF0.179 in its last earnings report, beating expectations of -CHF0.203. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Coherus Biosciences?
Currently, no hedge funds are holding shares in CH:8C5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Coherus Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF6.21 (― Upside)
CHF6.21 (― Upside)
Blogger Sentiment
Bullish
CH:8C5 Sentiment 100%
Sector Average 61%
Sector Average 61%
Technicals
SMA
Negative
20 days / 200 days
Momentum
38.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-56.50%
Trailing 12-Months
Company Description
Coherus Biosciences
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
8C5 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys meaningful progress across clinical and commercial fronts: robust enrollment across multiple studies, encouraging early TAGMO signals with biomarker directionality, solid commercial momentum for LOQTORZI (+15% QoQ sales) and sustained cost/liability reductions. Offsetting risks include a sizable quarter-over-quarter cash decline (~ -36.9%), an unachieved $37.5M milestone in Q2, immature clinical datasets that could change post-data cleaning, and ongoing commercial adoption/dosing frictions. On balance, the highlights (pipeline enrollment, early efficacy signals, revenue growth, expense reductions and liability improvements) outweigh the lowlights, though near-term execution and data maturation remain critical.View all CH:8C5 earnings summaries